Sachiko Tanaka

Sachiko Tanaka

Auto-generated profile, based on publicly available information

Sachiko Tanaka

Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2013 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
XHXiaomei Hu
Xiaomei Hu
BYBo Yuan
Bo Yuan
STSachiko Tanaka
Sachiko Tanaka
QZQingbing Zhou
Qingbing Zhou
KOKenji Onda
Kenji Onda
THToshihiko Hirano
Toshihiko Hirano
Arsenic disulfide (As₂S₂) has been traditionally used to treat certain types of leukemia. However, a detailed mechanism of action of As₂S₂ is not sufficiently documented. The effects of As₂S₂ on HL-60 cells were therefore investigated by focusing on proliferation, differentiation, generation of reactive oxygen species (ROS), intracellular glutathione (GSH) depletion and activation of p38 mitogen-activated protein kinase (MAPK). As₂S₂ at 0.5-8 μM induced cell differentiation based on an increment in CD11b expression, nitroblue tetrazolium (NBT)-positive cells and cell size change. A transient increase in ROS level along with intracellular GSH level was also observed. p38 MAPK activation gradually increased after ROS generation and was sustained during cell differentiation. Decreased CD11b expression was accompanied by p38 MAPK activation, and a p38 MAPK inhibitor restored CD11b expression. The results suggest that moderate levels of oxidative stress induced by As₂S₂ correlate with HL-60 cell differentiation. Suppression of p38 MAPK can augment the efficacy of As₂S₂ to induce HL-60 cell differentiation.

24 August 2015 in Translational Oncology
Verified
Journal Article
Open access
AKAnna Kiyomi
Anna Kiyomi
MMMasujiro Makita
Masujiro Makita
TOTomoko Ozeki
Tomoko Ozeki
NLNa Li
Na Li
ASAiko Satomura
Aiko Satomura
俊平俊 彦 平野
俊 彦 平野
Several cytokines secreted from breast cancer tissues are suggested to be related to disease prognosis. We examined Th1/Th2/Th17 cytokines produced from three-dimensionally cultured breast cancer tissues and related them with patient clinical profiles. 21 tumor tissues and 9 normal tissues surgically resected from breast cancer patients were cultured in thermoreversible gelatin polymer-containing medium. Tissue growth and Th1/Th2/Th17 cytokine concentrations in the culture medium were analyzed and were related with hormone receptor expressions and patient clinical profiles. IL-6 and IL-10 were expressed highly in culture medium of both cancer and normal tissues. However, IFN-γ, TNF-α, IL-2, and IL-17A were not detected in the supernatant of the three-dimensionally cultured normal mammary gland and are seemed to be specific to breast cancer tissues. The growth abilities of hormone receptor-negative cancer tissues were significantly higher than those of receptor-positive tissues (P=0.0383). Cancer tissues of stage ≥IIB patients expressed significantly higher TNF-α levels as compared with those of patients with stage <IIB (P=0.0096). The tumor tissues resected from breast cancer patients can grow in the three-dimensional thermoreversible gelatin polymer culture system and produce Th1/Th2/Th17 cytokines. Hormone receptor-positive cancer tissues showed less growth ability. TNF-α is suggested to be a biomarker for the cancer stage.

1 May 2020 in Clinical Therapeutics
Verified
Journal Article
Closed access
MEMio Endo
Mio Endo
RHRyohei Hirano
Ryohei Hirano
HSHiromi Shibasaki
Hiromi Shibasaki
AYAkitomo Yokokawa
Akitomo Yokokawa
TFTakashi Furuta
Takashi Furuta
KMKatsumi Mizuno
Katsumi Mizuno

1 October 2013 in Cell Medicine
Verified
Journal Article
Open access
HSHiroyasu Sasahara
Hiroyasu Sasahara
KSKentaro Sugiyama
Kentaro Sugiyama
MTMahoto Tsukaguchi
Mahoto Tsukaguchi
KIKazuya Isogai
Kazuya Isogai
ATAkira Toyama
Akira Toyama
THToshihiko Hirano
Toshihiko Hirano
The lymphocyte immunosuppressant sensitivity test (LIST) using patient peripheral lymphocytes can predict the therapeutic efficacy of immunosuppressive drugs used in renal transplantation. We have evaluated the pharmacological efficacy of drugs by using the LIST with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, which measures the cellular mitochondrial activity. The LIST with the MTT assay requires a relatively large amount of blood. As such, we developed a new assay for examining drug sensitivity with a CellTiter-Glo assay, which measures the amount of cellular ATP to help increase the assay's sensitivity and reduce the amount of blood needed. Renal transplant recipients generally receive either cyclosporine or tacrolimus, in addition to mycophenolate mofetil and methylprednisolone, as an immunosuppressive therapy to prevent acute rejection. We evaluated the pharmacological efficacy of these immunosuppressive agents with both the MTT and CellTiter-Glo assays using the peripheral blood mononuclear cells of 21 healthy volunteers. Furthermore, we also examined the relationship between these immunosuppressive agents' pharmacological efficacy and the results of the MTT and CellTiter-Glo assays. The IC50 values for cyclosporine, tacrolimus, mycophenolic acid, and methylprednisolone were significantly correlated between the MTT and CellTiter-Glo assays. The amount of blood cells required for LIST with the CellTiter-Glo assay was able to be reduced to 25% of the amount required for the previously established LIST with the MTT assay procedure. We concluded from these observations that the LIST with the CellTiter-Glo assay should be used instead of the MTT assay for carrying out individualized immunosuppressive therapy in renal transplantation patients.

1 September 2018 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
MMMasayuki Masuda
Masayuki Masuda
HUHiroya Utsumi
Hiroya Utsumi
STSachiko Tanaka
Sachiko Tanaka
AMAkemi Bd Maeno
Akemi Bd Maeno
MYMamiko Bd Yamamoto
Mamiko Bd Yamamoto
HAHitoshi Aizawa
Hitoshi Aizawa
Objectives The objective of this study was to investigate the influence of treatment with cholinesterase inhibitors (ChEIs) and calcineurin inhibitors (CNIs) on the occurrence of cramps in myasthenia gravis (MG) patients. Methods The frequency and duration of cramp and serum electrolytes were evaluated in 81 patients with MG. The patients were classified using Myasthenia Gravis Foundation of America postintervention status scores based on the treatment and the responsiveness to the treatment. Quantitative MG score, MG activities of daily living score, MG composite score, or MG quality of life 15 score was used to assess the health-related quality of life (QOL). Results Muscle cramps developed in 44 (54.3%) of 81 MG patients. The scores of MG activities of daily living, MG composite, or MG-QOL 15-item questionnaire in patients with cramp were significantly higher than those in patients without cramps (P = 0.002, P = 0.01, or P = 0.0022, respectively). The serum magnesium concentrations were lower in patients treated with CNI (n = 16) than in those not treated with CNI (n = 65) (P = 0.002). The probability of cramps was significantly higher in patients treated with ChEIs (≥180 mg/d) in addition to CNI than in patients who were treated with a low dose of ChEIs (≤60 mg/d) without concomitant CNI treatment (P = 0.017). Conclusions Our data suggested that treatment with a high dose of ChEI and CNI accelerated the probability of cramps and reduced the QOL in MG patients.

13 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MOMasaaki Okihara
Masaaki Okihara
HTHironori Takeuchi
Hironori Takeuchi
YKYukiko Kikuchi
Yukiko Kikuchi
IAIsao Akashi
Isao Akashi
YKYu Kihara
Yu Kihara
俊平俊 彦 平野
俊 彦 平野
Recently, steroid reduction/withdrawal regimens have been attempted to minimize the side effects of steroids in renal transplantation. However, some recipients have experienced an increase/resumption of steroid administrations and acute graft rejection (AR). Therefore, we investigated the relationship between the individual lymphocyte sensitivity to steroids and the clinical outcome after steroid reduction/withdrawal. We cultured peripheral blood mononuclear cells (PBMCs) isolated from 24 recipients with concanavalin A (Con A) in the presence of methylprednisolone (MPSL) or cortisol (COR) for four days, and the 50% of PBMC proliferation (IC50) values and the PBMC sensitivity to steroids were calculated. Regarding the experience of steroid increase/resumption and incidence of AR within one year of steroid reduction/withdrawal, the IC50 values of these drugs before transplantation in the clinical event group were significantly higher than those in the event-free group. The cumulative incidence of steroid increase/resumption and AR in the PBMC high-sensitivity groups to these drugs before transplantation were significantly lower than those in the low-sensitivity groups. These observations suggested that an individual’s lymphocyte sensitivity to steroids could be a reliable biomarker to predict the clinical outcome after steroid reduction/withdrawal and to select the patients whose dose of steroids can be decreased and/or withdrawn after transplantation.